Altimmune, Inc. (ALT) Presents at Morgan Stanley 23rd Annual

Company Overview - Altimmune is focused on developing a GLP-1 glucagon dual receptor agonist aimed at treating serious liver diseases, particularly MASH [1] - The drug, named pemvidutide, is designed to have direct effects on the liver while also providing metabolic benefits [1] Mechanism of Action - Glucagon has a direct effect on the liver, while GLP-1 contributes to metabolic benefits such as weight loss [2] - The optimal approach to treating MASH involves targeting the liver directly [2]